Home / Investors / Startups / Wugen

Wugen

Wugen is developing off-the-shelf cellular therapies targeting solid tumors and hematologic malignancies

About Wugen

Wugen is developing off-the-shelf cellular therapies for cancer. Our NK cell therapy products originate from healthy donors and are further manipulated in order to enhance their function to eliminate cancer cells. Our NK cell and CAR-T immuno-oncology therapies address the needs of patients with solid tumors, acute myeloid leukemia (AML) and T-cell malignancies.

Industries

Investors in Wugen (4)